D-0170-2017 Class III Terminated

Recalled by Teva Pharmaceuticals USA — North Wales, PA

FDA drug recall D-0170-2017 was initiated by Teva Pharmaceuticals USA on Nov 1, 2016 and is designated Class III. Reason for recall: Failed Content Uniformity: Product was out of specification for spray content uniformity obtained during stability testing. The recall status is terminated (terminated Feb 6, 2018). Affected quantity: 201, 234 Canisters.

Recall details

Product Type
Drugs
Report Date
Dec 14, 2016
Initiation Date
Nov 1, 2016
Termination Date
Feb 6, 2018
Voluntary/Mandated
Voluntary: Firm initiated
Product Quantity
201, 234 Canisters

Product description

Qnasl (beclomethasone dipropionate) Nasal Aerosol 40 Mcg, 60 Metered Sprays, Rx only, Manufactured for Teva Respiratory, LLC, Horsham, PA 19044, By: 3M Drug Delivery Systems, Northridge, CA 91324, NDC 59310-206-06 and 59310-206-08 (Physician Samples).

Reason for recall

Failed Content Uniformity: Product was out of specification for spray content uniformity obtained during stability testing.

Distribution pattern

Nationwide

Code information

Lot #: 150096, Exp. 3/2017; Lot #: 150327, Exp. 10/2017

Source

Dataset
openFDA drug recall enforcement reports
FDA record
This recall in openFDA (JSON)
Enforcement Report
Search FDA's Enforcement Report for D-0170-2017
openFDA file date
Nov 16, 2026
Loaded by RegDataLab
Nov 17, 2026

These dates say when openFDA published the data file and when RegDataLab last loaded it.

Source: openFDA record for D-0170-2017. Report a data issue: hello@regdatalab.com.